To Determine if Chromium Nicotinate Supplementation Will Improve Insulin Resistance in HIV Patients With Metabolic Abnormalities

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00152893
Recruitment Status : Completed
First Posted : September 9, 2005
Last Update Posted : July 19, 2013
Canadian Foundation for AIDS Research (CANFAR)
Information provided by (Responsible Party):
Johane Allard, University Health Network, Toronto

Brief Summary:
In HIV patients, fasting insulin levels decrease with chromium supplementation. This study is to determine if chromium nicotinate supplementation at 400ug/day for 16 weeks will improve insulin resistance in HIV patients with metabolic abnormalities.

Condition or disease Intervention/treatment Phase
HIV Infections Drug: chromium nicotinate Drug: Placebo Phase 2

Detailed Description:
This study is a randomized, double-blind, placebo-controlled, crossover study where patients will be supplemented for 16 weeks with either chromium nicotinate 400 ug/day or placebo and then crossover to the opposite treatment for another 16 weeks. Each soft gel capsule of chromium contains 200ug of chromium and patients will take 1 capsule twice a day or its placebo. Placebo contains di-calcium phosphate in a soft gel capsule and its appearance is similar to the chromium capsules.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 52 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: The Effects of Chromium Supplementation on Glucose and Lipid Metabolism in Patients With HIV Infection
Study Start Date : August 2002
Actual Primary Completion Date : February 2008
Actual Study Completion Date : February 2008

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Chromium
400 μg (200 μg pills, twice per day) of Cr-nicotinate
Drug: chromium nicotinate
Placebo Comparator: Placebo
Identical looking placebo (di-calcium phosphate)
Drug: Placebo

Primary Outcome Measures :
  1. insulin resistance calculated using fasting glucose and fasting insulin levels in blood [ Time Frame: BL & 16 weeks ]

Secondary Outcome Measures :
  1. hemoglobin A1c (HbA1c) [ Time Frame: BL & 16 weeks ]
  2. blood lipid profile (triglycerides [TG], cholesterol or high-density lipoprotein [HDL]) [ Time Frame: BL & 16 weeks ]
  3. body composition by dual energy x-ray absorptiometry (DEXA) scan, bioelectric impedance analysis and skin fold measurement [ Time Frame: BL & 16 weeks ]
  4. oxidative stress [ Time Frame: BL & 16 weeks ]
  5. plasma chromium [ Time Frame: BL & 16 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • HIV documented patients will be considered for the study if they have at least one abnormality with respect to fasting blood glucose, TG, total or HDL cholesterol. Normal fasting glucose is defined as < 6.1 mmol/L. Hypertriglyceridemia is defined as concentrations above 2.0 mmol/L on the basis of reports of increased risk of cardiac disease. Hypercholesterolemia is defined as concentrations above 5.5 mmol/L and a low HDL-cholesterol concentration as less than 0.9 mmol/L.
  • Patients will need to be on a stable drug regimen for at least 8 weeks and not taking any chromium supplement or chromium-containing multivitamins 4 weeks prior to and during the study period. Patients can stay on their hypoglycemic or lipid-lowering medications and the required dosage will be monitored.

Exclusion Criteria:

  • Patients will be excluded if there is concomitant acute infection or malignancy.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00152893

Canada, Ontario
University Health Network - Toronto General Hospital
Toronto, Ontario, Canada, M5G 2C4
Sponsors and Collaborators
Johane Allard
Canadian Foundation for AIDS Research (CANFAR)
Principal Investigator: Johane Allard, MD, FRCPC University Health Network - Toronto General Hospital

Publications of Results:
Other Publications:
Responsible Party: Johane Allard, Gastroenterologist, Prof. of Medicine, University Health Network, Toronto Identifier: NCT00152893     History of Changes
Other Study ID Numbers: 03-0703-A
015 027
First Posted: September 9, 2005    Key Record Dates
Last Update Posted: July 19, 2013
Last Verified: July 2013

Keywords provided by Johane Allard, University Health Network, Toronto:
blood sugar > 6.1 mmol/l
triglycerides > 2 mmol/l
total cholesterol > 5.5 mmol/l or HDL < 0.9 mmol/l

Additional relevant MeSH terms:
HIV Infections
Acquired Immunodeficiency Syndrome
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Slow Virus Diseases
Nicotinic Acids
Trace Elements
Growth Substances
Physiological Effects of Drugs
Hypolipidemic Agents
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents
Vasodilator Agents
Vitamin B Complex